Dantrolene Sodium and Drospirenone, ethinyl estradiol, and levomefolate
Determining the interaction of Dantrolene Sodium and Drospirenone, ethinyl estradiol, and levomefolate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using ethinyl estradiol and dantrolene can cause serious side effects that may affect your liver. Call your doctor immediately if you experience a fever, chills, joint pain or swelling, excessive tiredness or weakness, unusual bleeding or bruising, skin rash or itching, loss of appetite, nausea, vomiting, or yellowing of the skin or the whites of your eyes. If your doctor does prescribe these medications together, you may need a dose adjustment or special tests to safely take both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: The use of estrogens may potentiate the risk of hepatotoxicity associated with dantrolene therapy. The mechanism of interaction is unknown. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity nature have been reported during dantrolene use. Although a definite drug interaction with estrogen therapy has not yet been established, hepatotoxicity has occurred more often in women over 35 years of age receiving concomitant estrogen therapy than in other patients treated with dantrolene.
MANAGEMENT: Dantrolene should be used with caution in patients, particularly females over 35 years of age, who are receiving concomitant estrogen therapy. Liver function tests (SGOT, SGPT, alkaline phosphatase, total bilirubin) should be performed prior to and during dantrolene therapy at appropriate intervals, and the drug should generally be withheld if significant abnormalities are observed. Patients treated with dantrolene should be advised to promptly contact their physician if they develop signs and symptoms of hepatocellular injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. The drug should be discontinued if hepatitis is suspected, since early detection and drug withdrawal will increase the likelihood of reversing the damage. Following resolution of clinical and laboratory abnormalities, reinstitution of dantrolene therapy should be attempted with extreme caution and only if benefit clearly outweighs the risk.
- "Product Information. Dantrium (dantrolene)." Procter and Gamble Pharmaceutic, Cincinnati, OH.
Generic Name: dantrolene
Brand name: Dantrium, Dantrium Intravenous, Revonto, Ryanodex
Synonyms: Dantrolene
Generic Name: drospirenone / ethinyl estradiol / levomefolate calcium
Brand name: Beyaz, Safyral, Rajani, Tydemy
Synonyms: Ethinyl Estradiol, Drospirenone, and Levomefolate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dantrolene Sodium-DroTuss-CP
- Dantrolene Sodium-Droxia
- Dantrolene Sodium-Droxidopa
- Dantrolene Sodium-Dry Eye Omega Benefits
- Dantrolene Sodium-DryMax
- Dantrolene Sodium-DryMax Syrup
- Drospirenone, ethinyl estradiol, and levomefolate-Dapagliflozin
- Drospirenone, ethinyl estradiol, and levomefolate-Dapagliflozin and metformin
- Drospirenone, ethinyl estradiol, and levomefolate-Dapagliflozin and Metformin Extended-Release Tablets
- Drospirenone, ethinyl estradiol, and levomefolate-Dapagliflozin and saxagliptin
- Drospirenone, ethinyl estradiol, and levomefolate-Dapagliflozin Propanediol
- Drospirenone, ethinyl estradiol, and levomefolate-Dapsone